[go: up one dir, main page]

MX2010008460A - Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular. - Google Patents

Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.

Info

Publication number
MX2010008460A
MX2010008460A MX2010008460A MX2010008460A MX2010008460A MX 2010008460 A MX2010008460 A MX 2010008460A MX 2010008460 A MX2010008460 A MX 2010008460A MX 2010008460 A MX2010008460 A MX 2010008460A MX 2010008460 A MX2010008460 A MX 2010008460A
Authority
MX
Mexico
Prior art keywords
vap
inhibitor
thiazole derivative
prophylaxis
symbol
Prior art date
Application number
MX2010008460A
Other languages
English (en)
Inventor
Tatsuya Matsukawa
Kazuhiro Masuzaki
Yosuke Kawai
Akiko Kawasaki
Akiko Akasaka
Makoto Takewaki
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of MX2010008460A publication Critical patent/MX2010008460A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención provee un novedoso derivado de tiazol útil en forma de un inhibidor de VAP-1, un agente farmacéutico para la profilaxis o tratamiento de enfermedades asociadas a la VAP-1 y similares; un compuesto representado por la fórmula (I): R1-NH-X-Y-Z (I) donde cada símbolo es como se define en la especificación, o su sal farmacéuticamente aceptable.
MX2010008460A 2008-01-31 2009-01-30 Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular. MX2010008460A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008021588 2008-01-31
PCT/JP2009/052015 WO2009096609A1 (en) 2008-01-31 2009-01-30 Thiazole derivative and use thereof as vap-1 inhibitor

Publications (1)

Publication Number Publication Date
MX2010008460A true MX2010008460A (es) 2010-08-30

Family

ID=40546096

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008460A MX2010008460A (es) 2008-01-31 2009-01-30 Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.

Country Status (17)

Country Link
US (1) US8507690B2 (es)
EP (4) EP2639229B9 (es)
JP (1) JP5415430B2 (es)
KR (1) KR101622414B1 (es)
CN (1) CN101932568B (es)
AR (1) AR070336A1 (es)
AU (1) AU2009209885B2 (es)
BR (1) BRPI0906352A2 (es)
CA (1) CA2712962C (es)
DK (1) DK2639229T3 (es)
ES (2) ES2452834T3 (es)
MX (1) MX2010008460A (es)
NZ (1) NZ587205A (es)
PT (1) PT2639229E (es)
RU (1) RU2496776C9 (es)
TW (1) TWI437986B (es)
WO (1) WO2009096609A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
UA112154C2 (uk) * 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
US8802666B2 (en) * 2009-12-21 2014-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibitors of cyclophilins and uses thereof
TWI594764B (zh) * 2010-04-12 2017-08-11 生化治療公司 治療用途
HUE028394T2 (en) 2011-03-15 2016-12-28 Astellas Pharma Inc Guanidine compound
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
JP2018080113A (ja) 2015-05-27 2018-05-24 株式会社アールテック・ウエノ 脳梗塞処置剤
JP2018076236A (ja) 2015-06-05 2018-05-17 株式会社アールテック・ウエノ がんを処置するための医薬組成物
FR3037954B1 (fr) * 2015-06-24 2017-08-11 Michelin & Cie Procede de synthese de molecules azo-dicarbonylees porteuses de groupes associatifs
WO2017098236A1 (en) 2015-12-07 2017-06-15 Proximagen Limited Vap-1 inhibitors for treating pain
CA3039890A1 (en) * 2016-11-28 2018-05-31 Teijin Pharma Limited Therapeutic drug or prophylactic drug for diabetic nephropathy
CN113924290A (zh) * 2019-05-09 2022-01-11 范因斯坦医学研究院 硫代半肼基甲酸酯及其用途
US11883461B2 (en) 2019-05-09 2024-01-30 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
WO2020227603A1 (en) 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Hmgb1 antagonist
SE544131C2 (en) * 2020-03-16 2022-01-04 Pvac Medical Tech Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
EP4177245A1 (en) * 2020-07-10 2023-05-10 Adama Agan Ltd. Process and intermediates for the preparation of fenoxasulfone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1181871B (it) 1985-04-01 1987-09-30 Consiglio Nazionale Ricerche Inibitori selettivi delle benzilamminossidasi rispetto ad altre amminossidasi
TW205041B (es) * 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
EP0639972A1 (en) 1992-05-15 1995-03-01 University Of Saskatchewan Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
PL360374A1 (en) * 2000-07-05 2004-09-06 Biotie Therapies Corporation Inhibitors of copper-containing amine oxidases
ES2168084B1 (es) 2000-11-07 2003-11-16 Univ Barcelona Combinacion de aminas y compuestos de vanadio (iv) (v) para el tratatamiento y/o la prevencion de la diabetes mellitus.
WO2002038153A1 (en) 2000-11-09 2002-05-16 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
AR042941A1 (es) * 2003-01-27 2005-07-06 Fujisawa Pharmaceutical Co Derivados de tiazol, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos inhibidores de la proteina-1 de adhesion vascular (vap-1)
CN100491361C (zh) * 2003-01-27 2009-05-27 安斯泰来制药有限公司 噻唑衍生物及其作为vap-1抑制剂的用途
CN1794988B (zh) * 2003-03-31 2010-07-28 株式会社·R-技术上野 用于治疗血管渗透性过高疾病的组合物
CA2558135C (en) 2004-03-18 2012-08-14 R-Tech Ueno, Ltd. Aqueous composition comprising thiazole derivative
DE602005013793D1 (de) 2004-07-27 2009-05-20 Astellas Pharma Inc Thiazolderivate mit vap-1-hemmender wirkung
CA2579889A1 (en) * 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
WO2008066145A1 (en) 2006-11-30 2008-06-05 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor
EP2172221A4 (en) * 2007-06-25 2010-06-23 R Tech Ueno Ltd COMPOSITION FOR OPHTHALMIC DISEASE ASSOCIATED WITH HYPOXIA OR ISCHEMIA
TW200927100A (en) * 2007-10-19 2009-07-01 R Tech Ueno Ltd Pharmaceutical composition for treating cataract

Also Published As

Publication number Publication date
DK2639229T3 (da) 2015-02-02
CA2712962A1 (en) 2009-08-06
AU2009209885A1 (en) 2009-08-06
NZ587205A (en) 2012-06-29
RU2496776C9 (ru) 2014-12-20
TW200934488A (en) 2009-08-16
CA2712962C (en) 2016-08-16
EP2676955B1 (en) 2015-03-11
JP2011510911A (ja) 2011-04-07
EP2252604B1 (en) 2014-01-08
US20110015240A1 (en) 2011-01-20
HK1185348A1 (en) 2014-02-14
HK1152293A1 (en) 2012-02-24
WO2009096609A1 (en) 2009-08-06
PT2639229E (pt) 2015-02-04
AR070336A1 (es) 2010-03-31
EP2650287B9 (en) 2015-08-05
RU2010136301A (ru) 2012-03-10
JP5415430B2 (ja) 2014-02-12
EP2252604A1 (en) 2010-11-24
KR101622414B1 (ko) 2016-05-18
EP2676955A1 (en) 2013-12-25
ES2452834T3 (es) 2014-04-02
AU2009209885B2 (en) 2013-12-05
TWI437986B (zh) 2014-05-21
BRPI0906352A2 (pt) 2015-07-07
CN101932568A (zh) 2010-12-29
EP2639229B9 (en) 2015-08-05
EP2639229A3 (en) 2013-12-25
RU2496776C2 (ru) 2013-10-27
US8507690B2 (en) 2013-08-13
ES2527014T3 (es) 2015-01-19
CN101932568B (zh) 2014-08-06
KR20100112623A (ko) 2010-10-19
EP2650287A1 (en) 2013-10-16
EP2639229B1 (en) 2014-11-26
EP2639229A2 (en) 2013-09-18
EP2650287B1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
MX2012000766A (es) Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
SG179418A1 (en) Inhibitors of the hedgehog pathway
AU2012214029A8 (en) Rorgammat inhibitors
JO2892B1 (en) CYP inhibitors 17
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
TN2011000053A1 (en) Organic compounds
TW200833663A (en) Therapeutic agents
GEP20146125B (en) Aminopyrimidines as syk inhibitors
TN2011000400A1 (en) Inhibitors of beta-secretase
JO2848B1 (en) Organic compounds
TN2010000038A1 (en) Organic compounds
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MX2010008921A (es) Derivados de oxazolidinona.
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
TN2012000092A1 (en) Therapeutic agent for mood disorders
MX2008016358A (es) Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
IN2012DN02502A (es)

Legal Events

Date Code Title Description
FG Grant or registration